EBMT

Haematopoietic Stem Cell Transplantation (HSCT) in Europe 2006. A Preliminary Report from The EBMT Activity Survey Office.


The trends in the 2006 Annual Survey comply with previous surveys: there is still an increase in HSCT in Europe when compared to 2005 in most indications and donor types. Leukaemias were the main indications in absolute numbers for allogeneic HSCT and lymphoproliferative disorders for autologous HSCT. There appear to be fewer autologous transplants for leukaemias and fewer allogeneic and autologous transplants for solid tumours.  Of interest is the continuing increase in cord blood transplants.

All EBMT member teams and affiliated transplant centres were asked to report their transplants in 2006 by disease indication, donor type and stem cell source as outlined in the table. The survey has followed the same concept since its introduction in 1990 and is part of the EBMT quality control system and the JACIE accreditation programme. At the time of this report, 510 teams from 39 countries have reported their 2006 data. This corresponds to 82% of the 620 contacted teams and includes a total of 21’713 first HSCT, 8’439 allogeneic (39%) and 13’274 autologous (61%) HSCT. There were an additional 3’295 procedures, 1’388 re-transplants for rejection or relapse and 1’907 additional transplants as part of a planned multiple transplant programme. Main indications in 2006 were leukaemias (32%) with 5’958 allogeneic and 1’029 autologous HSCT, lymphoproliferative disorders (57%) with 1’459 allogeneic and 10’904 autologous HSCT, solid tumours (6%) with 68 allogeneic and 1’193 autologous HSCT and non malignant diseases (5%) with 882 allogeneic and 120 autologous HSCT. The survey is incomplete with 18% of teams still missing, but a few trends are already clear. The data indicate an ongoing increase in all HSCT, allogeneic and autologous with a few exceptions: There were fewer autologous HSCT for leukaemias, with a main reduction in acute lymphoblastic leukemias and there were fewer allogeneic and autologous HSCT for solid tumours in general. Lower numbers have been reported for both breast and renal cancer. The trend towards the primary use of peripheral blood for HSCT continues and comprises 98% of the stem cell products in the autologous and 71% in the allogeneic setting. An increase in the use of cord blood as stem cell source is also noteworthy. The 438 cord blood transplants reported so far to the survey represents 5% of all allogeneic and 10% of all unrelated HSCT.

The EBMT activity survey office will attempt to publish the completed survey soon. All teams who have not yet reported are kindly asked to send in their data as soon as possible. The EBMT activity survey team is open for any questions, criticisms or suggestions for future analyses.

(To view image in a larger format please click here)

For information on how to report data to the EBMT Activity Survey, please click here.

A. Gratwohl, H. Baldomero
EBMT Activity Survey Office
University Hospitals Basel
CH-4031 Basel
Switzerland
Tel: +41 61 265 3203
FAX:+41 61 265 2735